Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
Nattopharma ASA, Oslo, Norway.
J Thromb Haemost. 2021 May;19(5):1348-1363. doi: 10.1111/jth.15289. Epub 2021 Mar 28.
Vitamin K antagonists (VKA) and non-vitamin K oral antagonist anticoagulants (NOAC) are used in the clinic to reduce risk of thrombosis. However, they also exhibit vascular off-target effects. The aim of this study is to compare VKA and NOAC on atherosclerosis progression and calcification in an experimental setup.
Female Apoe mice (age 12 weeks) were fed Western-type diet as control or supplemented with dabigatran etexilate or warfarin for 6 or 18 weeks. Vascular calcification was measured in whole aortic arches using µCT and [ F]-NaF. Atherosclerotic burden was assessed by (immuno)histochemistry. Additionally, in vitro effects of warfarin, thrombin, and dabigatran on primary vascular smooth muscle cells (VSMC) were assessed.
Short-term treatment with warfarin promoted formation of atherosclerotic lesions with a pro-inflammatory phenotype, and more rapid plaque progression compared with control and dabigatran. In contrast, dabigatran significantly reduced plaque progression compared with control. Long-term warfarin treatment significantly increased both presence and activity of plaque calcification compared with control and dabigatran. Calcification induced by warfarin treatment was accompanied by increased presence of uncarboxylated matrix Gla protein. In vitro, both warfarin and thrombin significantly increased VSMC oxidative stress and extracellular vesicle release, which was prevented by dabigatran.
Warfarin aggravates atherosclerotic disease activity, increasing plaque inflammation, active calcification, and plaque progression. Dabigatran lacks undesired vascular side effects and reveals beneficial effects on atherosclerosis progression and calcification. The choice of anticoagulation impacts atherosclerotic disease by differential off target effect. Future clinical studies should test whether this beneficial effect also applies to patients.
维生素 K 拮抗剂 (VKA) 和非维生素 K 口服抗凝剂 (NOAC) 用于临床以降低血栓形成风险。然而,它们也表现出血管非靶标作用。本研究旨在比较 VKA 和 NOAC 在实验模型中对动脉粥样硬化进展和钙化的影响。
雌性 Apoe 小鼠(年龄 12 周)喂食西方饮食作为对照或补充达比加群酯或华法林,持续 6 或 18 周。使用 µCT 和 [F]-NaF 测量整个主动脉弓的血管钙化。通过(免疫)组织化学评估动脉粥样硬化负担。此外,还评估了华法林、凝血酶和达比加群对原代血管平滑肌细胞 (VSMC) 的体外作用。
短期华法林治疗促进了动脉粥样硬化病变的形成,表现出促炎表型,并与对照和达比加群相比,斑块进展更快。相比之下,达比加群治疗显著减缓了斑块进展。长期华法林治疗与对照和达比加群相比,显著增加了斑块钙化的存在和活性。华法林治疗引起的钙化伴随着未羧化基质 Gla 蛋白的存在增加。在体外,华法林和凝血酶均显著增加了 VSMC 的氧化应激和细胞外囊泡释放,而达比加群则可预防这种增加。
华法林加重动脉粥样硬化疾病的活动度,增加斑块炎症、活性钙化和斑块进展。达比加群缺乏不良的血管副作用,并显示出对动脉粥样硬化进展和钙化的有益作用。抗凝选择通过不同的非靶标作用影响动脉粥样硬化疾病。未来的临床研究应测试这种有益作用是否也适用于患者。